Medipharm Labs Corp (LABS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 731 | 790 | 717 | 617 | 692 |
| Accounts receivable | 319 | -616 | 5,772 | -230 | 900 |
| Other Working Capital | -575 | 528 | 5,171 | 1,288 | -952 |
| Other Operating Activity | -2,081 | -2,228 | -10,186 | -4,907 | -8,170 |
| Operating Cash Flow | $-1,606 | $-1,526 | $1,474 | $-3,232 | $-7,530 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 21 | 326 | -1,725 | 0 | N/A |
| Net Acquisitions | N/A | N/A | 4,249 | 0 | N/A |
| Other Investing Activity | -56 | 199 | 1,784 | 1,643 | 946 |
| Investing Cash Flow | $-35 | $525 | $4,308 | $1,643 | $946 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -153 | -269 | 1,371 | -388 | -67 |
| Other Financing Activity | 838 | 203 | -1,612 | 89 | 1,158 |
| Financing Cash Flow | $685 | $-66 | $-241 | $-299 | $1,091 |
| Exchange Rate Effect | 21 | 12 | -510 | 96 | 85 |
| Beginning Cash Position | 16,926 | 17,981 | 12,950 | 14,742 | 20,150 |
| End Cash Position | 15,991 | 16,926 | 17,981 | 12,950 | 14,742 |
| Net Cash Flow | $-956 | $-1,067 | $5,541 | $-1,888 | $-5,493 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,606 | -1,526 | 1,474 | -3,232 | -7,530 |
| Capital Expenditure | -56 | -21 | -119 | -260 | -67 |
| Free Cash Flow | -1,662 | -1,547 | 1,355 | -3,492 | -7,597 |